Over the past 18 months since launching AdverseEvents Explorer as a paid subscription software-as-a-service application, the growth that we have realized has been phenomenal. Innovative and forward thinking organizations such as Memorial Hermann, University of Utah Medical Center, and Medstar Georgetown University Hospital, to name a few, have incorporated our drug safety data, analytics, and insight into their decision making and pharmacy processes. To specifically see how Memorial Hermann is realizing return on investment, read a recent article in Becker’s Hospital Review, A new era of drug safety: Using adverse events big data to improve outcomes and decrease healthcare costs.

In a healthcare world where maintaining the status quo is the norm and “tight budgets” often the excuse, to avoid innovation and disruption of established workflows, it’s been amazing to watch the way cutting-edge organizations accept new methodologies and lead the way to improved patient outcomes and lower system-wide costs. Our mission to redefine drug safety requires that every health plan, payer, system, and hospital start opening themselves up to innovative technologies and become receptive to the quality insights that big data analytics has brought to their doorsteps. 

As our clients have told us, to have this level of data available and not use it in drug decision making is a detriment to patient safety, and just plain bad business.

We recognize our responsibility in helping to define the value and necessity of incorporating post-approval drug safety data and comparative safety research into P&T decisions, daily pharmacy workflows, and drug price negotiations.

As such, we are releasing our Drug Safety Monitor comparative safety research reports, free-of-charge to our qualified colleagues within the healthcare community (criteria below) to help further this effort. 

This service publishes comparative analyses utilizing data and analytics found in AdverseEvents Explorer. Each report provides safety reviews for newly launched (and soon-to-be launched) drugs vs. current market standard, deep dives into FDA safety communications and warnings, as well as contextual commentary on other drug safety issues.  Recent topics have included:

Ketoacidosis due to SGLT-2 inhibitors in Type-2 Diabetes: From RxSignal to FDA safety

Hypercholesterolemia: Safety Analysis of PCSK-9 inhibitors; evolocumab and alirocumab vs. Lipitor

Cost Comparison and Safety Analysis of Eylea vs. Lucentis for Diabetic Retinopathy

As we strive to ensure that drug safety data transparency becomes the norm in the healthcare community, our releasing of the Drug Safety Monitor research to qualified individuals is our attempt to help push the industry further and faster. The Drug Safety Monitor reports will be delivered via email and provide direct links to each report that is published (typically 1-3 a week), as well as access to all past reports. 

To qualify, you must:

  1. Be currently affiliated with a health plan, PBM, health system, or hospital – must have a valid institutional email address
  2. Be a member of a P&T committee or support formulary or pharmacy decisions at your organization
  3. Be committed to improving drug safety

To register, please contact your sales representative or fill out this brief registration.

 

Subscribe to Drug Safety Monitor



Jim Davis

Jim Davis

Executive Vice President

Jim Davis Linkedintwitter

 

Jim Davis

Written by Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.